Latest & greatest articles for atrial fibrillation

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on atrial fibrillation or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on atrial fibrillation and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for atrial fibrillation

621. Warfarin for Atrial Fibrillation Stroke Prevention

Warfarin for Atrial Fibrillation Stroke Prevention Warfarin for Atrial Fibrillation Stroke Prevention – TheNNTTheNNT Oral anticoagulants in non-valvular atrial fibrillation for primary stroke prevention (no prior stroke) 25 for prevented stroke In Summary, for those who took the warfarin (for 1.5 years): Benefits in NNT 96% saw no benefit 4% were helped by preventing 1 stroke 2.4% were helped by avoiding death 1 in 25 were helped (preventing stroke ) 1 in 42 were helped (preventing death from (...) any cause) Harms in NNT 4% were harmed by having bleeding 0.26% were harmed by intracranial hemorrhage 1 in 25 were harmed (having bleeding) 1 in 384 were harmed (intracranial hemorrhage) View As: NNT % Source: Efficacy Endpoints: All ischemic strokes, All cause mortality (within 30 days from stroke) Harm Endpoints: All intracranial hemorrhages, Major extracranial hemorrhage Narrative: Non-valvular atrial fibrillation (AF) is the most common cause of cardio-embolic stroke and a powerful risk

theNNT2010

622. Efficacy and safety of catheter ablation versus antiarrhythmic drugs for atrial fibrillation: a meta-analysis of randomized trials

Efficacy and safety of catheter ablation versus antiarrhythmic drugs for atrial fibrillation: a meta-analysis of randomized trials Efficacy and safety of catheter ablation versus antiarrhythmic drugs for atrial fibrillation: a meta-analysis of randomized trials Efficacy and safety of catheter ablation versus antiarrhythmic drugs for atrial fibrillation: a meta-analysis of randomized trials Bonanno C, Paccanaro M, La Vecchia L, Ometto R, Fontanelli A CRD summary The authors concluded (...) that radiofrequency catheter ablation was a relatively effective and well-tolerated procedure to cure atrial fibrillation in selected patients, but that further research is required to confirm the review findings. This was a well-conducted review and the authors’ cautious conclusions are likely to be reliable. Authors' objectives To evaluate the efficacy and safety of radiofrequency catheter ablation in patients with atrial fibrillation. Searching MEDLINE, CINAHL, the Cochrane Central Register of Controlled

DARE.2010

623. Cardioblate ablation systems (Medtronic Inc.) for atrial fibrillation

Cardioblate ablation systems (Medtronic Inc.) for atrial fibrillation Cardioblate ablation systems (Medtronic Inc.) for atrial fibrillation Cardioblate ablation systems (Medtronic Inc.) for atrial fibrillation Citation Cardioblate ablation systems (Medtronic Inc.) for atrial fibrillation. Lansdale: HAYES, Inc.. 2010 Authors' objectives Atrial fibrillation (AF) is the most commonly diagnosed cardiac rhythm disturbance and it is characterized by rapid, uncoordinated contractions of the upper (...) chambers of the heart. Although AF occurs in a high percentage of patients who have mitral valve disease, it can also occur in individuals who have no associated cardiac abnormalities. During AF, atrial blood flow can become relatively stagnant, allowing clots to form that can cause strokes. In addition, the atrial arrhythmia can spread to the lower chambers of the heart, causing dangerous ventricular arrhythmias that may result in loss of blood pressure, fainting, heart attack, or death. AF is usually

Health Technology Assessment (HTA) Database.2010

624. Dronedarone for the treatment of non-permanent atrial fibrillation

Dronedarone for the treatment of non-permanent atrial fibrillation Dronedarone for the treatment of non-permanent atrial fibrillation Dronedarone for the treatment of non-permanent atrial fibrillation National Institute for Health and Clinical Excellence Record Status This is a bibliographic record of a published health technology assessment. No evaluation of the quality of this assessment has been made for the HTA database. Citation National Institute for Health and Clinical Excellence (...) . Dronedarone for the treatment of non-permanent atrial fibrillation. London: National Institute for Health and Clinical Excellence (NICE). Technology Appraisal Guidance 197. 2010 Authors' conclusions Dronedarone is recommended as an option for the treatment of non-permanent atrial fibrillation only in people: • whose atrial fibrillation is not controlled by first-line therapy (usually including beta-blockers), that is, as a second-line treatment option, and • who have at least one of the following

Health Technology Assessment (HTA) Database.2010

625. Ablation procedures for rhythm control in patients with atrial fibrillation: clinical and cost-effectiveness analyses

Ablation procedures for rhythm control in patients with atrial fibrillation: clinical and cost-effectiveness analyses Ablation procedures for rhythm control in patients with atrial fibrillation: clinical and cost-effectiveness analyses Ablation procedures for rhythm control in patients with atrial fibrillation: clinical and cost-effectiveness analyses Assasi N, Blackhouse G, Xie F, Gaebel K, Robertson D, Hopkins R, Healey J, Roy D, Goeree R Record Status This is a bibliographic record (...) of a published health technology assessment from a member of INAHTA. No evaluation of the quality of this assessment has been made for the HTA database. Citation Assasi N, Blackhouse G, Xie F, Gaebel K, Robertson D, Hopkins R, Healey J, Roy D, Goeree R. Ablation procedures for rhythm control in patients with atrial fibrillation: clinical and cost-effectiveness analyses. Ottawa: Canadian Agency for Drugs and Technologies in Health (CADTH). Technology report no. 128. 2010 Authors' conclusions The evidence

Health Technology Assessment (HTA) Database.2010

626. Extending the boundaries of cardiac resynchronization therapy: efficacy in atrial fibrillation, New York Heart Association class II, and narrow QRS heart failure patients

Extending the boundaries of cardiac resynchronization therapy: efficacy in atrial fibrillation, New York Heart Association class II, and narrow QRS heart failure patients Extending the boundaries of cardiac resynchronization therapy: efficacy in atrial fibrillation, New York Heart Association class II, and narrow QRS heart failure patients Extending the boundaries of cardiac resynchronization therapy: efficacy in atrial fibrillation, New York Heart Association class II, and narrow QRS heart (...) with wide QRS intervals; patients with atrial fibrillation versus those with sinus rhythm; and patients with New York Heart Association (NYHA) Class II symptoms versus patients with NYHA Class III/IV symptoms. Searching MEDLINE and Cochrane Central Register of Controlled Trials (CENTRAL) were searched from inception to December 2008 for relevant English-language studies; search terms were reported. Reference lists of retrieved articles were checked to identify additional references. Study selection

DARE.2010

627. Are calcium channel blockers superior to digoxin for controlling the ventricular rate in patients with recent onset atrial fibrillation?

Are calcium channel blockers superior to digoxin for controlling the ventricular rate in patients with recent onset atrial fibrillation? BestBets: Are calcium channel blockers superior to digoxin for controlling the ventricular rate in patients with recent onset atrial fibrillation? Are calcium channel blockers superior to digoxin for controlling the ventricular rate in patients with recent onset atrial fibrillation? Report By: Richard Parris - Locum Consultant Emergency Medicine Search checked (...) by Simon Clarke - Consultant Emergency Medicine Institution: Emergency Department Royal Bolton Hospital Date Submitted: 9th September 2004 Date Completed: 17th December 2009 Last Modified: 18th December 2009 Status: Green (complete) Three Part Question In a stable patient with [acute atrial fibrillation], is [treatment superior] with [calcium channel blockers or digoxin]? Clinical Scenario A 57 year old woman attends the Emergency Department with palpitations of uncertain duration. A diagnosis

BestBETS2010

628. Efficacy and safety of prescription omega-3 fatty acids for the prevention of recurrent symptomatic atrial fibrillation: a randomized controlled trial.

Efficacy and safety of prescription omega-3 fatty acids for the prevention of recurrent symptomatic atrial fibrillation: a randomized controlled trial. 21078810 2010 12 01 2010 12 02 2016 10 17 1538-3598 304 21 2010 Dec 01 JAMA JAMA Efficacy and safety of prescription omega-3 fatty acids for the prevention of recurrent symptomatic atrial fibrillation: a randomized controlled trial. 2363-72 10.1001/jama.2010.1735 Atrial fibrillation (AF) is common, yet there remains an unmet medical need (...) for additional treatment options. Current pharmacological treatments have limited efficacy and significant adverse events. Limited data from small trials suggest omega-3 polyunsaturated fatty acids may provide a safe, effective treatment option for AF patients. To evaluate the safety and efficacy of prescription omega-3 fatty acids (prescription omega-3) for the prevention of recurrent symptomatic AF. Prospective, randomized, double-blind, placebo-controlled, parallel-group multicenter trial involving 663 US

JAMA2010

629. Efficacy and safety of dabigatran compared with warfarin at different levels of international normalised ratio control for stroke prevention in atrial fibrillation: an analysis of the RE-LY trial.

Efficacy and safety of dabigatran compared with warfarin at different levels of international normalised ratio control for stroke prevention in atrial fibrillation: an analysis of the RE-LY trial. 20801496 2010 09 20 2010 09 30 2016 06 22 1474-547X 376 9745 2010 Sep 18 Lancet (London, England) Lancet Efficacy and safety of dabigatran compared with warfarin at different levels of international normalised ratio control for stroke prevention in atrial fibrillation: an analysis of the RE-LY trial (...) Med. 2011 Jan 18;154(2):JC1-6 21242360 Lancet. 2011 Feb 5;377(9764):464-5; author reply 465 21296230 Administration, Oral Adult Aged Anticoagulants administration & dosage adverse effects therapeutic use Atrial Fibrillation complications Benzimidazoles administration & dosage adverse effects therapeutic use Dabigatran Drug Administration Schedule Female Hemorrhage chemically induced Humans International Normalized Ratio Male Middle Aged Pyridines administration & dosage adverse effects therapeutic

Lancet2010

630. Comparison of antiarrhythmic drug therapy and radiofrequency catheter ablation in patients with paroxysmal atrial fibrillation: a randomized controlled trial.

Comparison of antiarrhythmic drug therapy and radiofrequency catheter ablation in patients with paroxysmal atrial fibrillation: a randomized controlled trial. 20103757 2010 01 27 2010 02 03 2016 10 25 1538-3598 303 4 2010 Jan 27 JAMA JAMA Comparison of antiarrhythmic drug therapy and radiofrequency catheter ablation in patients with paroxysmal atrial fibrillation: a randomized controlled trial. 333-40 10.1001/jama.2009.2029 Antiarrhythmic drugs are commonly used for prevention of recurrent (...) atrial fibrillation (AF) despite inconsistent efficacy and frequent adverse effects. Catheter ablation has been proposed as an alternative treatment for paroxysmal AF. To determine the efficacy of catheter ablation compared with antiarrhythmic drug therapy (ADT) in treating symptomatic paroxysmal AF. A prospective, multicenter, randomized (2:1), unblinded, Bayesian-designed study conducted at 19 hospitals of 167 patients who did not respond to at least 1 antiarrhythmic drug and who experienced at least 3 AF

JAMA2010

631. Lenient versus strict rate control in patients with atrial fibrillation.

Lenient versus strict rate control in patients with atrial fibrillation. 20231232 2010 04 15 2010 04 22 2010 11 18 1533-4406 362 15 2010 Apr 15 The New England journal of medicine N. Engl. J. Med. Lenient versus strict rate control in patients with atrial fibrillation. 1363-73 10.1056/NEJMoa1001337 Rate control is often the therapy of choice for atrial fibrillation. Guidelines recommend strict rate control, but this is not based on clinical evidence. We hypothesized that lenient rate control (...) is not inferior to strict rate control for preventing cardiovascular morbidity and mortality in patients with permanent atrial fibrillation. We randomly assigned 614 patients with permanent atrial fibrillation to undergo a lenient rate-control strategy (resting heart rate <110 beats per minute) or a strict rate-control strategy (resting heart rate <80 beats per minute and heart rate during moderate exercise <110 beats per minute). The primary outcome was a composite of death from cardiovascular causes

NEJM2010

632. Percutaneous occlusion of the left atrial appendage in non-valvular atrial fibrillation for the prevention of thromboembolism (IPG349)

Percutaneous occlusion of the left atrial appendage in non-valvular atrial fibrillation for the prevention of thromboembolism (IPG349) Percutaneous occlusion of the left atrial appendage in non-valvular atrial fibrillation for the prevention of thromboembolism | Guidance and guidelines | NICE Percutaneous occlusion of the left atrial appendage in non-valvular atrial fibrillation for the prevention of thromboembolism Interventional procedures guidance [IPG349] Published date: June 2010 Share (...) control is assigned. In addition the ICD-10 code I48.X Atrial fibrillation and flutter would be recorded. Your responsibility This guidance represents the view of NICE, arrived at after careful consideration of the evidence available. When exercising their judgement, healthcare professionals are expected to take this guidance fully into account. However, the guidance does not override the individual responsibility of healthcare professionals to make decisions appropriate to the circumstances

National Institute for Health and Clinical Excellence - Interventional Procedures2010

633. Dronedarone for the treatment of non-permanent atrial fibrillation (TA197)

Dronedarone for the treatment of non-permanent atrial fibrillation (TA197) Dronedarone for the treatment of non-permanent atrial fibrillation | Guidance and guidelines | NICE Dronedarone for the treatment of non-permanent atrial fibrillation Technology appraisal guidance [TA197] Published date: 25 August 2010 Last updated: 01 December 2012 Share Guidance for details of the decision and the revised marketing authorisation). The therapeutic indication of the revised marketing authorisation is now (...) with non-permanent atrial fibrillation who have had a procedure called cardioversion to correct an irregular heart rhythm. Who can have dronedarone? You should be able to have dronedarone if: you have already tried another type of drug (usually a drug called a beta-blocker) but this has not worked and other options have been considered and you have at least 1 of the following which means you are at a higher risk of developing disease of the heart or blood vessels: - you are taking at least 2 different

National Institute for Health and Clinical Excellence - Technology Appraisals2010

634. Morbidity and Mortality With Warfarin Therapy Use in Elderly Patients With Atrial Fibrillation: A Systematic Review

Morbidity and Mortality With Warfarin Therapy Use in Elderly Patients With Atrial Fibrillation: A Systematic Review "Morbidity and Mortality With Warfarin Therapy Use in Elderly Patients " by Kristi M. Crowell < > > > > > Title Author Date of Award 8-14-2010 Degree Type Capstone Project Degree Name Master of Science in Physician Assistant Studies First Advisor Mark Pedemonte, MD Second Advisor Annjanette Sommers MS, PAC Third Advisor Rob Rosenow PharmD, OD Rights . Abstract Background (...) : Atrial fibrillation (AF) is the most common dysrhythmia among elderly patients. A co-morbidity associated with this disease process is embolic stroke. In an effort to reduce the potential morbidity and mortality associated with stroke, patients are often placed on the anticoagulant warfarin. While warfarin has been statistically proven to reduce the rate of embolic stroke in patients with AF, it potentiates increased risk of bleeding. The elderly population has an elevated level of AF and increased risk for fall

Pacific University EBM Capstone Project2010

635. Practical Rate & Rhythm Management of Atrial Fibrillation

Practical Rate & Rhythm Management of Atrial Fibrillation SM Practical Rate and Rhythm Management of Atrial Fibrillation POCKET GUIDE Adapted from the ACC/AHA/ESC 2006 Guidelines for the Management of Patients With Atrial Fibrillation WWW.HRSonlinE.oRG Editor: Bradley P . Knight, MD, FHRS Assistant Editors: Matthew Sorrentino, MD, M. Craig Delaughter, MD, Ph.D., Dipak P . Shah, MD The Practical Rate and Rhythm Management for the Cardiologist Pocket Guide was adapted from the ACC/AHA/ESC 2006 (...) Guidelines for the Management of Patients With Atrial Fibrillation. A Report of the American College of Cardiology (ACC)/American Heart Association (AHA)Task Force on Practice Guidelines and the European Society of Cardiology (ESC) Committee for Practice Guidelines (Writing Committee to Revise the 2001 Guidelines for the Management of Patients With Atrial Fibrillation). Developed in Collaboration With the European Heart Rhythm Association (EHRA) and the Heart Rhythm Society (HRS). ©2010 Heart Rhythm

Heart Rhythm Society2010

636. Rhythm control and stroke prevention strategies for patients with atrial fibrillation

Rhythm control and stroke prevention strategies for patients with atrial fibrillation Rhythm control and stroke prevention strategies for patients with atrial fibrillation Rhythm control and stroke prevention strategies for patients with atrial fibrillation Institute for Clinical and Economic Review (ICER) Record Status This is a bibliographic record of a published health technology assessment. No evaluation of the quality of this assessment has been made for the HTA database. Citation (...) Institute for Clinical and Economic Review (ICER). Rhythm control and stroke prevention strategies for patients with atrial fibrillation. Boston: Institute for Clinical and Economic Review (ICER). 2010 Authors' objectives Atrial fibrillation (AF) is the most common cardiac arrhythmia seen in clinical practice, affecting approximately 2.5 million persons in the U.S. AF is not only common but also carries significant risks of mortality and morbidity, raising the risk of stroke more than five-fold

Health Technology Assessment (HTA) Database.2010

637. Effects of rosuvastatin on atrial fibrillation occurrence: ancillary results of the GISSI-HF trial

Effects of rosuvastatin on atrial fibrillation occurrence: ancillary results of the GISSI-HF trial 19717850 2009 10 02 2010 07 14 2015 11 19 1522-9645 30 19 2009 Oct European heart journal Eur. Heart J. Effects of rosuvastatin on atrial fibrillation occurrence: ancillary results of the GISSI-HF trial. 2327-36 10.1093/eurheartj/ehp357 This ancillary analysis of the GISSI-HF database aims at assessing the effect of rosuvastatin on the occurrence of atrial fibrillation (AF) in patients (...) with chronic heart failure (HF) who were not in AF at study entry. GISSI-HF was a double-blind, placebo-controlled trial testing n-3 PUFA and rosuvastatin vs. corresponding placebos in patients with chronic HF. Atrial fibrillation occurrence was defined as the presence of AF in the electrocardiogram (ECG) performed at each visit during the trial or AF as a cause of worsening HF or hospital admission or as an event during hospitalization. Among the 3690 patients (80.7%) without AF on their baseline ECG

EvidenceUpdates2009

638. Alcohol and illicit drug use as precipitants of atrial fibrillation in young adults: a case series and literature review

Alcohol and illicit drug use as precipitants of atrial fibrillation in young adults: a case series and literature review 19699381 2009 08 24 2009 09 09 2009 08 24 1555-7162 122 9 2009 Sep The American journal of medicine Am. J. Med. Alcohol and illicit drug use as precipitants of atrial fibrillation in young adults: a case series and literature review. 851-856.e3 10.1016/j.amjmed.2009.02.012 Atrial fibrillation in young patients (atrial fibrillation in patients presenting with "lone atrial fibrillation" precipitated by alcohol or illicit drugs. We retrospectively analyzed young (defined as atrial fibrillation who were admitted to the hospital with electrocardiographically confirmed diagnosis of atrial fibrillation or atrial flutter, precipitated

EvidenceUpdates2009

639. N-Terminal Pro-B-Type Natriuretic Peptide Is a Major Predictor of the Development of Atrial Fibrillation. The Cardiovascular Health Study

N-Terminal Pro-B-Type Natriuretic Peptide Is a Major Predictor of the Development of Atrial Fibrillation. The Cardiovascular Health Study 19841297 2009 11 03 2009 12 30 2016 12 03 1524-4539 120 18 2009 Nov 03 Circulation Circulation N-terminal pro-B-type natriuretic peptide is a major predictor of the development of atrial fibrillation: the Cardiovascular Health Study. 1768-74 10.1161/CIRCULATIONAHA.109.873265 Atrial fibrillation (AF), the most common cardiac rhythm abnormality, is associated (...) with significant morbidity, mortality, and healthcare expenditures. Elevated B-type natriuretic peptide levels have been associated with the risk of heart failure, AF, and mortality. The relation between N-terminal pro-B-type natriuretic peptide (NT-proBNP) and AF was studied in 5445 Cardiovascular Health Study participants with the use of relative risk regression for predicting prevalent AF and Cox proportional hazards for predicting incident AF. NT-proBNP levels were strongly associated with prevalent AF

EvidenceUpdates2009 Full Text: Link to full Text with Trip Pro

640. Glucocorticoid use and risk of atrial fibrillation or flutter: a population-based, case-control study

Glucocorticoid use and risk of atrial fibrillation or flutter: a population-based, case-control study 19822824 2009 10 13 2009 11 04 2009 10 13 1538-3679 169 18 2009 Oct 12 Archives of internal medicine Arch. Intern. Med. Glucocorticoid use and risk of atrial fibrillation or flutter: a population-based, case-control study. 1677-83 10.1001/archinternmed.2009.297 Glucocorticoid use is associated with increased risk of myocardial infarction, stroke, and heart failure, but data are limited (...) on the risk of atrial fibrillation or flutter. We examined whether glucocorticoid use is associated with the risk of atrial fibrillation or flutter. For this population-based, case-control study, we identified all patients with a first hospital diagnosis of atrial fibrillation or flutter from January 1, 1999, through December 31, 2005, in Northern Denmark (population, 1.7 million). For each case we selected 10 population controls matched by age and sex. We obtained data on glucocorticoid prescriptions

EvidenceUpdates2009